TrialClinical and experimental nephrology2021

Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.

Shigeo Horie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.